Ardena Expands Bioanalytical Services with New Lab in Oss, Netherlands, Enhancing Capabilities to Meet Growing Client Demand

  Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...

October 31, 2024 | Thursday | News
Jubilant Therapeutics Advances Innovative Cancer Therapies with First Patient Dosing in Global Trials for JBI-802 and JBI-778

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...

October 28, 2024 | Monday | News
Avantor CEO Michael Stubblefield Delivers “Just Another” Stellar Q3, Raises 2024 Free Cash Flow Guidance Again

Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...

October 28, 2024 | Monday | Company results
Kind Pharmaceutical Secures FDA Orphan Drug Designation for Sickle Cell Disease Treatment AND017

Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...

October 28, 2024 | Monday | News
Taiwan’s Bora Pharmaceuticals Expands Rare Disease Portfolio with Acquisition of U.S.-Based Pyros Pharmaceuticals

Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472),  announced that its Board of Directors has approved the acquisition of US-based ...

October 28, 2024 | Monday | News
AbbVie and Gedeon Richter Forge New Agreement to Explore Treatments for Neuropsychiatric Disorders

 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...

October 25, 2024 | Friday | News
Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria to be Unveiled at ACAAI 2024

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...

October 25, 2024 | Friday | News
Thermo Fisher CEO Marc N. Casper Highlights Strong Q3 2024 Results with $10.6 Billion Revenue and Breakthrough Innovations

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...

October 24, 2024 | Thursday | Company results
Florida Lung Health Coalition and DELFI Diagnostics Launch Initiative to Transform Lung Cancer Screening

In a groundbreaking alliance announced, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc. (NASDAQ: RDNT), and the Ame...

October 23, 2024 | Wednesday | News
Grifols Partners with BARDA to Develop Eye Drops for Sulfur Mustard Ocular Injury

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has established a...

October 23, 2024 | Wednesday | News
Biogen to Showcase Promising Data on Felzartamab at Kidney Week 2024

Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...

October 23, 2024 | Wednesday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News
Ionis and AstraZeneca's WAINZUA Recommended for EU Approval for Hereditary Amyloidosis Treatment

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Comm...

October 22, 2024 | Tuesday | News
Agilent Technologies Introduces Next-Generation InfinityLab LC Series with Innovative Assist Technology, Transforming Lab Automation and Efficiency

Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...

October 22, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close